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Abstract:  
Objective: Pathogenic variants in SCN8A have been associated with a wide spectrum of epilepsy 
phenotypes, ranging from benign familial infantile seizures (BFIS) to epileptic encephalopathies 
with variable severity. Furthermore, a few patients with intellectual disability (ID) or movement 
disorders without epilepsy have been reported. The vast majority of the published SCN8A patients 
suffers from severe developmental and epileptic encephalopathy (DEE). In this study, we aimed to 
provide further insight on the spectrum of milder SCN8A-related epilepsies. 
Methods: A cohort of 1095 patients was screened using a next-generation sequencing panel. 
Further patients were ascertained from a network of epilepsy genetics clinics. Patients with severe 
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Results: We found 36 probands who presented with a SCN8A-related epilepsy and normal intellect 
(33%) or mild (61%) to moderate ID (6%). All patients presented with epilepsy between age 1.5 
months and seven years (mean 13.6 months), and 58% of these became seizure free, 2/3 on 
monotherapy. Neurological disturbances included ataxia (28%) and hypotonia (19%) as the most 
prominent features. Interictal EEG was normal in 41%. Several recurrent variants were observed 
including Ile763Val, Val891Met, Gly1475Arg, Gly1483Lys, Phe1588Leu, Arg1617Gln, 
Ala1650Val/Thr, Arg1872Gln and Asn1877Ser. 
Significance: With this study, we explore the electro-clinical features of an intermediate SCN8A-
related epilepsy with mild cognitive impairment and for the majority a treatable epilepsy. 
 
 
Key words: SCN8A, voltage-gated sodium channels, epilepsy, epilepsy genetics, intellectual 
disability 
Introduction: 
SCN8A encodes the voltage-gated sodium channel Nav1.6, which is primarily expressed in 
excitatory neurons with high concentrations at the axon initial segment and the node of Ranvier. 
Pathogenic variants in SCN8A are associated with a spectrum of epilepsy phenotypes, ranging 
from rare families with benign familial infantile seizures (BFIS) to severe early onset 
developmental and epileptic encephalopathies (DEE) (EIEE13, OMIM #614558). Since the first case 
report published by Veeramah and colleagues in 2012
1
, several reports have confirmed the role of 
SCN8A, primarily in patients with DEE
2-9
. The majority of patients with SCN8A DEE, described so 
far, have a severe phenotype characterized by early seizure onset, difficult to treat seizures, 
severe intellectual disability (ID), motor disorders and a relatively high mortality
2-10
Functional studies of selected variants causing DEE, have revealed gain-of-function as the main 
pathogenic mechanism
. 
1; 6; 11; 12
. This gain-of-function comes from hyperactivity of the ion channel, 
due to elevated persistent sodium currents, hyperpolarizing shifts in the voltage dependence of 
activation or impaired channel current inactivation
12; 13
. This mechanism is the opposite of the one 
that has been demonstrated in Dravet syndrome, which is characterized by loss-of-function 
variants in SCN1A
14
. SCN1A encodes the voltage gated sodium channel Nav1.1, which is primarily 
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channel in the human CNS, can lead to both gain- and loss-of-function, complicating things even 
more
15
. Awareness of these important differences in pathophysiology is necessary, as it might 
have therapeutic implications
16




. We identified three unrelated families with a total of 16 family members who 
presented with BFIS and normal cognition. Five family members developed paroxysmal kinesigenic 
dyskinesia (PKD)
17




. Beside these two extreme phenotypes, there is an increasing number 
of patients with a milder form of DEE. In this study, we describe the spectrum of the electro-
clinical features of this intermediate SCN8A- epilepsy phenotype, aiming to provide a clearer 
picture for clinicians, genetic counselors and affected families. 
Methods and material: 
We systematically screened all exons and exon-intron boundaries of SCN8A in a cohort of 1095 
unselected patients with various forms of epilepsy using different next-generation sequencing 
(NGS) panels
19
. The panels included from 45 to 500+ genes related to epilepsy, intellectual 
disability or autism. Variants were assumed to be pathogenic if they arose de novo, or were 
inherited from an affected parent or affected/unaffected mosaic parent, and if they were non-
synonymous, splice-site altering or frameshift causing, and not present in controls in the gnomAD 
browser (see web resources). Sanger sequencing confirmed variants and segregation. 
Furthermore, detected variants were tested (PolyPhen-2, SIFT and MutationTaster) for predicted 
pathogenicity. ACMG and MPC scores are noted in table 1. All variants, except for one, were either 
pathogenic or likely pathogenic according to the ACMG criteria
20
Four different metrics were used for in silico variant pathogenicity prediction:  
. 
1) The ‘Missense badness, PolyPhen-2, and Constraint score’ (MPC), which demonstrates a 5.8 
times increased variant enrichment in cases compared to individuals from the general population 
for MPC scores >2
21
2) The ‘paralog conservation score’ (parazscore), which quantifies the amino-acid positions 
conservation across human proteins of the same gene family. A significant enrichment of disease-
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3) The Grantham score, which accesses the effect of the amino acid substitution based on the 
properties of the amino acid exchange. It ranks amino acid substitutions from similar amino acids 
substitiutions (0) to substitution which differs in their chemical properties ones (215)
23
4) The allele frequency analysis based on the alleleFrequencyApp (see web resources), which 
calculates a maximum credible number of possible pathogenic alleles observed in gnomAD. The 
allele count is estimated based on the disease prevalence, the allelic and genetic heterogeneity 
and the variant penetrance. For SCN8A we specified the disease prevalence as one in 300 the 
allelic heterogeneity as 0.01, the genetic heterogeneity as 0.1 and the penetrance as 50% resulting 
in a maximum number of a single allele in gnomAD. We compared the corresponding value with 
the allele frequency of variants present in gnomAD.  
. 
 
SCN8A positive patients underwent a detailed clinical evaluation and patients with severe DEE and 
BFIS were excluded from the study. The criteria for severe DEE were defined as severe, 
pharmacoresistant epilepsy and developmental impairment, as previously reported 
24
. BFIS is a 
self-limiting epilepsy syndrome characterized by afebrile seizures typically in clusters, with onset 
between four and eight months. Neurological examination, psychomotor development and the 
interictal EEG are normal and the children become seizure free within the first years of life and 
sustain seizure freedom without the aid of antiepileptic drugs (AEDs)
25
Additional probands were collected from an international network of epilepsy genetics clinics. 
Data on clinical phenotype, genetics, neuroimaging and EEG were requested for all patients (and if 
possible relatives), who were included in the study. Seizures were classified according to the 
International League Against Epilepsy (ILAE)
. 
26
Sodium channel blockers (SCBs) were defined as AEDs that target sodium channels and included 
carbamazepine (CBZ), oxcarbazepine(OXC), lamotrigine(LTG) and phenytoin (PHT). 
. All probands, and in case of minors, legal parents, 
provided written informed consent. The study was approved by the local ethical committees. 
Data sharing: anonymized data will be shared by request from any qualified investigator. 
 
Results: 
By the use of targeted NGS screening of SCN8A in a cohort of 1095 patients, we identified 12 
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criteria for a severe DEE and thus excluded from this study. Of the 1095 patients screened, 
approximately 326 fulfilled a DEE diagnosis (this might be an underestimate, as referrals to our 
center are often lacking clinical information). In addition to the remaining six patients, we 
ascertained 30 additional probands/families with predicted pathogenic SCN8A variants through 
collaborating diagnostic and research laboratories. The Asn1877Ser variant was seen in three 
controls in gnomAD, but as the phenotype resembles a benign familial epilepsy, with several 
family members affected, and was seen in three probands in this study, it was included as being 
pathogenic. All variants, except #10 p.Tyr1241Cys, were classified as pathogenic or likely 
pathogenic according to the ACMG criteria
20
. Not all missense variants in SCN8A are pathogenic 
and at 384 amino acid positions variants have been reported in the general population
27
Distinguishing disease-causing variants from benign is still a challenge in clinical genetics. Rarity of 




The patient variant 10 (c.3722A>G, p.Tyr1241Cys, NM_014191.3) was found once in the gnomAD
 (ACMG guidelines, but the key question “how common is too common?” remains 
poorly answered for many diseases.) Estimating the genetic and allelic heterogeneity offers an 
opportunity to identify variant cut-off frequency filters. Genetic heterogeneity is the maximum 
proportion of disease that is attributable to variation in a single gene, and allelic heterogeneity is 





 database. The presence of a variant in databases represents not a pathogenicity 
exclusion criterion based on our allele frequency analysis for mild forms of epilepsy. The amino 
acid residue position is relatively conserved across voltage-gated sodium channels (positive 
parazscore of 0.23
22
One of the probands (#30) has previously been mentioned briefly
). In addition, the MPC score (MPC = 2.48) supports variant pathogenicity and 
the Grantham score of 194 indicates a likely pathogenic variant. 
29
In total, 36 probands/families were included. The detected SCN8A variants were mainly missense 
variants (33/36) scattered throughout the gene. In addition, two truncating variants (one 
frameshift (#4) and one stop (#30)), and one variant causing a nucleotide change eight basepairs 
upstream of the start codon (#1) were detected. Fourteen variants were located in the 
transmembrane domains and two in the poreforming domain, of the cytoplasmic variants, we 
, but was included in this study 
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found one in the D1/D2 domain. The variant Asn544fs* was a frameshift variant with a clinical 
picture of absence epilepsy, inherited from an affected parent, and classified pathogenic according 
to the ACMG classification guidelines. 
The variants either occurred de novo or segregated within the family in a dominant fashion (#2, 
#4, #7, #14, #15, #33 and #34, see figure 1 for selected pedigrees). In the family of proband #33 
the variant was inherited from an affected mosaic parent. Mosaicism was also suspected in #15, 
but has not yet been confirmed. All variants were located at highly conserved residues and 
predicted possibly damaging according to computational prediction software (see methods and 
web resources). Mining the available literature and databases, eight variants were found to be 










5; 7; 8; 33; 34
, Ala1650Val
5; 7; 35
 (different amino acid 
substitution, see discussion section), Arg1872Gln
7; 12; 36
 and Asn1877 Ser
30; 35; 37
Clinical data on all 36 probands and families are presented in table 1. Age at inclusion varied from 
nine months to 35 years, with a mean of 7.9 years. Seizure onset was between six weeks and 
seven years, with a mean of 13.6 months (SD ±17 m). Seizure semiology was very diverse, and 
included generalized tonic-clonic seizures (GTCs) (21), focal (14), tonic (8), myoclonic (6) and 
atonic seizures (8), as well as epileptic spams (2) and atypical / typical absences (12). Seizure 
severity did not progress over time and seizure triggers were not found. Three probands 
experienced convulsive status epilepticus (#3, #14, #33).  
, with five of them 
(amino acid positions 763, 1475, 1617,1650, 1872) seen in severe DEE phenotypes as well.  
The interictal EEG was available in 33/36 patients and showed focal epileptiform abnormalities in 
15 patients (45%), predominant in the posterior quadrants in (ten patients) or in the central/ 
centro-parietal / fronto-central regions (five patients), with or without bilateral spreading. Four 
patients (12%) had only generalized abnormalities (#6, #14, #22, #26). In 14 patients (39%) the 
interictal EEG was normal (#9, #11, #12, #13, #16, #17, #20, #23, #29, #34, #35) or normalized at 
follow up (#15). Ictal EEG was available in four patients and showed a focal discharge in two (#6, 
#11) and generalized spike or irregular spike and waves discharges in the other two (#19, #28). 
Cognitively, these patients fare well. Before seizure onset 26/36 (72%) had normal cognitive 
development, two/36 (6%) had a mild ID, one/36 had moderate ID (3%) and four/36 (11%) had 
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deterioration from normal intellect/developmental delay to mild ID or from mild 
ID/developmental delay to moderate ID was seen in seven (19%) patients, whereas 81% did not 
experience deterioration at seizure onset. After seizure onset (and at the time of follow-up) 22/36 
(61%) had mild ID and two/36 (6%) had moderate ID.  
Additional features included ataxia (10/36), hypotonia (7/36), language delay (5/36), 
autism/autistic features (4/36), movement disorders (3/36) including paroxysmal dyskinesia 
(3/36), gait disturbances (2/36), sleep disturbances (1/36), learning difficulties (2/36) and ADHD 
(1/36). See table 1 for details. 
All probands were evaluated for their treatment response. Twenty-one/36 (58%) probands 
became seizure free. Monotherapy was sufficient in 12/21 (57%) probands, and included 
lamotrigine (LTG) (2), carbamazepine (CBZ) (1), phenytoin (PHT) (1), valproate (VPA) (1), vigabatrin 
(VGB) (1), ethosuximide (ETX) (1), phenobarbital (PB) (1) and levetiracetam (LEV) (1). In total 13/36 
(36%) probands became seizure free with therapy that included a SCB either in monotherapy or in 
combination with other antiepileptic drugs (AEDs). One became seizure free with a small dose of 
cannabidiol. However, 7/36 (20%) probands became seizure free without the use of SCBs. Seizure 
offset was only available for six patients, and ranged between four and 10 years, mean age at 
seizure offset was 7.7 years. 
Six probands had affected family members, segregating with the variants. For proband #5 a similar 
phenotype with absences and learning/language difficulties was seen in the sister, as well as the 
mother. For proband #7, the mother also had unspecified epilepsy and carried the variant; there 
was also an affected maternal grandfather, who did not have genetic analysis done. Likewise, 
proband #14 had an affected father, who carried the variant, and an affected paternal 
grandfather, who was not tested genetically. Proband #15 had a sister with a similar epilepsy 
phenotype, the variant was suspected to have been inherited from a mosaic parents, but this was 
not confirmed at the time of preparation of this paper. Proband #33 had an affected sister with a 
similar phenotype, and genetic investigations showed that the variant was inherited from an 
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Pathogenic variants in SCN8A have so far been described in patients with different epilepsy 
phenotypes, including rare families with BFIS and in >100 patients with mild to severe DEE. In this 
study, we describe the electro-clinical phenotype of 36 patients with intermediate epilepsies due 




The variant at position c.-8A>G was assumed to be likely pathogenic because it occurred de novo 
and the clinical features of the patient resembled the phenotype seen in other SCN8A patients. 
The variant is located outside of the Kozak consensus sequence, but may lead to increased RNA 
stability or translational initiation or result in altered splicing pattern. These theories can only be 
confirmed by functional testing of the variant, which unfortunately was not possible in this study. 
Until then, the variant may need to be classified as a variant of unknown significance. 
 were 
excluded from the study. 
All 36 patients presented with seizures in early childhood (mean 13.6 months). Before seizure 
onset, 72% probands had normal cognitive development. More than half of the probands became 
seizure free, 57% of these with monotherapy. Compared to the BFIS families, described by 
Gardella et al
17
, Anand et al
37
 and Han et al
18
, the majority of the probands in this cohort have 
cognitive impairment, with 6% suffering from moderate ID, and 61% from mild ID. Furthermore, 
only 58% became seizure free compared to almost 100% of the BFIS patients; seizure freedom is 
exceptional in the severe DEE phenotype. The patients herein described also appeared to have 
additional neurological disturbances including primarily ataxia (in 28%) and hypotonia (in 19%). In 
the severe DEE cohort, the incidence of ataxia is around 11%, compared to the 28% of this cohort. 
However, it is important to notice that many of the patients suffering from severe SCN8A DEE are 
unable to walk autonomously. Furthermore, the patients in this intermediate cohort do not suffer 
from the spasticity and paraplegia or the extra-pyramidal/cerebellar symptoms that up to 50% of 
the severe DEE patients do
24
In mouse models, it has been shown that SCN8A is widely expressed, both in the motor neurons of 
the brain stem, as well as in many types of neurons in the cerebellum, where functional deficits in 
Purkinje cells have been found
. A few patients in this cohort (8%) had dyskinesia, which is also seen 
in both severe DEEs and BFIS families. Growth impairment (microcephaly or reduced growth) 
observed in severe DEE, was not seen in this cohort. Other prominent phenotypic features 
included language delay/difficulties in 14% and movement disorders not further specified in 8%. 
38-40
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could explain the involvement of the motor system, and why cerebellar atrophy and ataxia
41
, 
associated with intellectual impairment, appeared to be major features in subjects harboring 
SCN8A variants. The cerebellum does, however, also play an important role in language and 
grammar processing, verbal working memory and speech motor planning
42
When comparing the present cohort to the severe SCN8A DEE population, in which the patients 
have earlier seizure onset, with more pronounced cognitive deficits as well as refractory epilepsy, 
we tried to identify possible predictive factors, that in newly diagnosed patients could help to 
detect those with a milder course as compared to those with a more severe evolution. First, within 
our cohort, the majority of probands have normal development prior to seizure onset (and 33% of 
them continue to develop normally) and maintain a normal EEG (41%). This is often not the case in 
probands who develop severe DEE, in which the majority usually are cognitively delayed from 
birth
, and a large proportion 
of SCN8A patients, including those reported in the present cohort, show an impairment of these 
functions as well.  
43
, or will present with cognitive difficulties early on and show changes in their EEGs. 
However, it is not an absolute feature, as we have observed several children with an extremely 
severe follow up, despite early normal development. Second, seizure onset occurred  at a mean 
age of 13.6 months, compared to a mean age of 4 months in the DEE group
43
Previously, it has been hypothesized, that seizures in patients with SCN8A variants should respond 
to SCBs 
. Anyway, it is worth 
to bear in mind that the age deviation in this cohort is quite large (SD±17 months), and thus these 
numbers should be interpreted carefully when counselling a family. Last, seizure freedom was 
obtained in 58% of the patients in this cohort and it was achieved rapidly and with monotherapy in 
2/3. In contrast, only about 5% of patients in the severe DEE cohort achieve seizure freedom with 
monotherapy. This is important, albeit also a prerequisite in this study, where the more severe 
epilepsies were excluded.  
16; 17
. A beneficial effect of SCBs was observed in 36% of the patients reported in this study, 
either as monotherapy or in combination with other AEDs, and supportive of this, previous studies 
have shown a gain-of-function of the Arg1617Gln and Arg1872Leu
12
 variants. Yet, 19% became 
seizure free without the use of SCBs, suggesting that seizure freedom should not be attributed 
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Interestingly, a partial benefit of LTG was also observed in the proband with a stop variant (#30). 
We can speculate that this unexpected finding may depend on genetic modifiers and differences 
in genetic background, or the fact that as the stop-codon is located at the c-terminal part of the 
protein, the transcript does not undergo nonsense-mediated decay.  
Furthermore, we found three variants, i.e. one eight basepairs upstream of the start codon (#1), 
one frameshift variant (#4) and one stop variant (#30), all suspected to be loss-of-function, and all 
of them associated with an epilepsy phenotype. Previously, it has been hypothesized, that loss-of-
function variants would not cause epilepsy
44
, but rather present with ID with or without motor 
function abnormalities, such as ataxia
2; 34; 41
. However, Blanchard et al. also describe a patient with 
epilepsy and ID, carrying a LOF variant
11
, and two existing Scn8a knock-out mice models, supports 
the notion of epilepsy also being a feature of LOF of NaV1.6
45; 46
Variants were found throughout the gene (see figure 3), including the transmembrane segments, 
cytoplasmic loops and the inactivation gate, thus location in the gene is likely not predictable of 
functional or clinical effects of the variant, however, the figure does display the fact that the 
majority of the variants are found in domain three and four, the inactivation gate and the c-
terminal, which may help guide variant interpretation. 
. Other ion channel genes, 
including SCN2A have been shown to have a similar clinical picture, where both GOF and LOF 
variants may cause epilepsy. The underlying functional causes are yet to be fully elucidated. 
Indeed, we identified several recurrent variants and observed a wide range of phenotypic 
variability for variant carriers. Ile763Val, Gly1475Arg, Arg1617Gln, Ala1650Val and Arg1872Gln 
were all seen in this study as well as in patients with DEE. Ile763Val has previously been described 
in a patient with intractable epilepsy and moderate ID
30
The Gly1475Arg variant is even more diverse and it has previously been identified in several 
patients, including a child with severe DEE, who died from probable SUDEP
, whereas we found it in two patients with 
focal epilepsy and mild ID (#5 and #6).  
10; 32
Arg1617Gln has been seen in several DEE patients previously, including a girl with severe DEE who 
died after terminal progression of her disease
. In this cohort, we 
found it in two patients with mild ID, and epilepsy controlled by SCBs. Both patients did suffer 
from hypotonia and ataxia.  
2, 17
, whereas we found it in two patients with mild ID 
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(language delay, dyskinesia) and their seizure onset was earlier (4 months), compared to the rest 
of this cohort. We also found the Arg1617Gln variant in one patient (#21), who displayed 
moderate ID as well as autism. Ala1650Val variant has not been described before (#26), but has 
been seen several times with a threonine (Ala1650Thr) substitution in patients with severe DEE
5; 7; 
35
. Arg1872Gln has also been seen several times in patients with severe DEE
7; 36
, however we 
found it in a sib pair, with normal intellect and focal epilepsy (#34). The Gly1483Lys variant has 
previously been described in BFIS
17
 
; the patient in this study (#18) carrying this variant has indeed 
a very mild phenotype; with only speech delay, sporadic seizures and discrete focal EEG 
abnormalities. Why some variants show phenotypic heterogeneity and other variants do not, 
remains elusive. Of course, differences in the amino acid substitution might explain some of the 
difference, but this is true for just a few of the variants. In other cases, genetic modifiers and 
differences in the genetic background could underlie these observations. Further studies are 
needed to investigate this further. 
In conclusion, this study we provide further insight on the phenotypic spectrum of SCN8A epilepsy 
by focusing an intermediate phenotype characterized by treatable epilepsy with a later age of 
onset, mildly impaired cognitive development, as well as variable but in general mild neurological 
disturbances. A positive response to epilepsy treatment, especially with SCBs, was observed. Even 
if a wide range of phenotypes related to SCN8A variants can be expected (see illustration in figure 
2), these findings highlight the presence of an increasing number of SCN8A patients with a 
phenotype of moderate severity.  
The partial overlapping of genetic and early clinical features in SCN8A-related epilepsies makes it 
difficult to provide proper counselling in these children so far. Further investigations are 
warranted to clarify this issue, as well as explore possible prognostic factors.  
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Key Bullets: 
• The phenotypic spectrum of SCN8A is wide, from BFIS to DEE 
• The intermediate phenotype is characterized by a treatable epilepsy and mild cognitive 
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Table 1. Clinical characteristics of the probands 
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into the right 
parasaggital 
regions 
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See fig. 1 
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: A: Atonic, AA: Atypical Absences, Ab: Absences, ADHD: Attention Deficit Hyperactivity Disorder, AMD: amantadine, BG: 
Background, CAE: Childhood Absence Epilepsy, CBZ: Carbamazepine, CLB: Clobazam, CLZ: Clonazepam, D:Domain, DD: Developmental 
Delay, ED: Epileptiform Discharges, FS: Febrile seizures, F: Focal, GTC: Generalized Tonic-Clonic, KD: Ketogenic diet, LAC: Lacosamide, LEV: 
Levetiracetam, LTG: Lamotrigine, , LZP: Lorazepam, MD: Moderate Intellectual Disability, MID: Mild Intellectual Disability, m: months, M: 
Myoclonic, NA: Not available, N: Normal, O: Occipital, OXC: Oxcarbazepine, P: Parietal, PER: Perampanel, PHT: Phenytoin, RFM: 
Rufinamide, S:SE: Status Epilepticus, ST: Stiripentol, S: Spasms, SW: Spike and Wave complexes, sz: Seizures, T: Tonic, TPM: Topiramate, 
VGB: Vigabatrin, VPA: Valproic Acid, y: years, ZNS: Zonisamide 
Figure legends: 
Figure 1. Pedigrees of SCN8A-related epilepsies showing segregation of the variant with the phenotype 
Figure 2. The spectrum of SCN8A-related epilepsy 
Figure 3. A partial display of published variants, with the recurrent DEE and known LOF variants, as well as those identified in this study 
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
epi_14705_f1.tiff
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
epi_14705_f2.tiff
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
epi_14705_f3.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
